Ono Pharmaceutical Co Ltd, one of Japan’s largest pharmaceutical companies, is to expand its oncology pipeline with the addition of more bispecific antibodies, a therapy type that is said to enable better precision medicine for treating cancer. Under a collaboration with Adimab LLC of the US, the Japanese company will have an option for exclusive rights to novel bispecific antibody candidates for the treatment of multiple cancers. The deal involves an undisclosed upfront payment, R&D funding, and success-based milestone payments.
